Bile Duct Cancer (Cholangiocarcinoma)

What to expect from Medical Oncology at Charleston Oncology

Understanding Bile Duct Cancer

Bile duct cancers are classified by their location within the bile duct system:

• Intrahepatic cholangiocarcinoma — forms within the bile ducts inside the liver; the most rapidly increasing subtype in incidence
• Perihilar (hilar) cholangiocarcinoma — forms at the junction where the left and right hepatic ducts meet outside the liver (also called Klatskin tumor); the most common subtype
• Distal cholangiocarcinoma — forms in the lower portion of the bile duct, near the small intestine

The location of the tumor determines the treatment approach and significantly influences surgical options and outcomes.

How Common Is Bile Duct Cancer?

Cholangiocarcinoma is diagnosed in approximately 8,000 Americans each year. While relatively rare, its incidence has been increasing — particularly for intrahepatic tumors. The disease most commonly affects adults over 65, though it can occur at younger ages, especially in individuals with underlying bile duct conditions or genetic predispositions.

Risk Factors

In many cases, no specific cause is identified. However, certain conditions are associated with increased risk:

• Primary sclerosing cholangitis (PSC) — a chronic inflammatory condition of the bile ducts
• Chronic liver disease or cirrhosis
• Liver fluke infection (Clonorchis sinensis, Opisthorchis viverrini) — more common in parts of Asia
• Choledochal cysts — congenital malformations of the bile ducts
• Biliary stones (hepatolithiasis)
• Inflammatory bowel disease — particularly ulcerative colitis
• Exposure to certain industrial chemicals (thorotrast, dioxin, nitrosamines)
• Obesity and metabolic syndrome — emerging as independent risk factors
• Hereditary conditions — Lynch syndrome, BRCA mutations, and others

Symptoms of Bile Duct Cancer

Bile duct cancer is often called a ‘silent’ cancer because early-stage disease frequently produces no symptoms. When symptoms do appear, they may include:

• Jaundice — yellowing of the skin and whites of the eyes due to bile duct obstruction
• Dark urine and pale or clay-colored stools
• Itching (pruritus) caused by bile salt accumulation in the skin
• Abdominal pain, particularly in the upper right quadrant
• Unexplained weight loss or loss of appetite
• Fever and chills — suggesting secondary infection or cholangitis
• Fatigue

Because these symptoms are often associated with obstruction — rather than a visible mass — bile duct cancer may not be identified until it has reached an advanced stage. Prompt evaluation by experienced specialists is essential.

Diagnosis

Diagnosing cholangiocarcinoma requires a systematic and often multimodal evaluation. At Charleston Oncology, patients benefit from a fully coordinated diagnostic workup that may include:

• Blood tests — liver function tests, CA 19-9, CEA, and other tumor markers
• Imaging — abdominal ultrasound, CT scan, MRI with MRCP (magnetic resonance cholangiopancreatography) to evaluate the bile ducts and liver
• PET/CT scan — to assess for distant metastases
• ERCP (Endoscopic Retrograde Cholangiopancreatography) — a procedure that allows direct visualization of the bile ducts and enables biopsy
• Percutaneous or endoscopic biopsy — to confirm the diagnosis histologically
• Molecular profiling — next-generation sequencing to identify actionable mutations (IDH1, FGFR2, BRAF, HER2, and others) that guide targeted therapy selection

Molecular testing is particularly important in cholangiocarcinoma, as a significant proportion of patients harbor mutations that can be targeted with approved therapies. Charleston Oncology ensures that appropriate biomarker testing is integrated into the diagnostic workup for every patient.

Treatment Options

Treatment strategy for bile duct cancer depends on the tumor’s location, stage, extent of spread, and the patient’s overall health and liver function. A multidisciplinary team approach is the standard of care.

Surgery

Surgical resection — when feasible — remains the only potentially curative treatment for bile duct cancer. Depending on tumor location, surgery may involve removal of part of the liver, bile ducts, and potentially the gallbladder or pancreatic head. Not all patients are surgical candidates; your oncologist will coordinate closely with hepatobiliary surgical specialists to evaluate resectability.

Chemotherapy

For patients with unresectable or metastatic disease, systemic chemotherapy is the foundation of treatment. The combination of gemcitabine and cisplatin has been the established first-line standard of care. Recent clinical advances — including the addition of durvalumab (an immune checkpoint inhibitor) to this regimen — have improved outcomes and represent the current standard per NCCN guidelines.

Targeted Therapy

Cholangiocarcinoma is one of the cancer types where molecular profiling has had a transformative impact. Several FDA-approved targeted therapies are available for specific mutations:

• FGFR2 fusion/rearrangement — pemigatinib, infigratinib, futibatinib
• IDH1 mutation — ivosidenib
• BRAF V600E mutation — BRAF/MEK inhibitor combinations
• HER2 amplification — HER2-directed therapies
• NTRK gene fusion — larotrectinib or entrectinib
• MSI-H / dMMR — immune checkpoint inhibitors (pembrolizumab)

Charleston Oncology ensures that molecular profiling is conducted for every eligible patient so that targeted therapy options are fully evaluated.

Immunotherapy

Immune checkpoint inhibitors have an expanding role in bile duct cancer. Durvalumab in combination with chemotherapy is now a first-line option. Pembrolizumab is approved for patients with MSI-H/dMMR tumors. Your oncologist will assess your tumor’s biomarker profile to determine whether immunotherapy is appropriate.

Radiation Therapy

Radiation may be used as adjuvant therapy following surgery, or for local disease control in patients who are not surgical candidates. Stereotactic body radiation therapy (SBRT) and other advanced techniques are available through the multidisciplinary care team.

Liver-Directed Therapies

For patients with intrahepatic cholangiocarcinoma confined to the liver, liver-directed therapies — including transarterial chemoembolization (TACE), transarterial radioembolization (TARE/Y-90), and hepatic arterial infusion (HAI) — may be considered in appropriate cases, typically in coordination with interventional radiology.

Clinical Trials

Charleston Oncology participates in oncology clinical trials through the Bon Secours St. Francis Cancer Care network. Given the rapid pace of development in bile duct cancer therapeutics, clinical trial participation may offer access to novel agents and combinations. Ask your oncologist whether a trial may be right for you.

Your Care Team

Bile duct cancer management requires close collaboration among specialists. At Charleston Oncology, your coordinated care team may include:

• Medical oncologists — directing systemic therapy and overall treatment strategy
• Hepatobiliary and gastrointestinal surgeons — evaluating and performing surgical resection
• Radiation oncologists — planning and delivering radiation therapy
• Gastroenterologists and interventional endoscopists — performing diagnostic and therapeutic ERCP
• Interventional radiologists — providing biliary drainage and liver-directed therapies
• Pathologists — providing expert histological and molecular analysis
• Oncology social workers and palliative care specialists — supporting quality of life and patient/caregiver well-being